ECSP014068A - Procedimiento para regular la angiogenesis utilizando proteina ryk - Google Patents

Procedimiento para regular la angiogenesis utilizando proteina ryk

Info

Publication number
ECSP014068A
ECSP014068A EC2001004068A ECSP014068A ECSP014068A EC SP014068 A ECSP014068 A EC SP014068A EC 2001004068 A EC2001004068 A EC 2001004068A EC SP014068 A ECSP014068 A EC SP014068A EC SP014068 A ECSP014068 A EC SP014068A
Authority
EC
Ecuador
Prior art keywords
ryk
angiogenesis
diseases
procedure
proteins
Prior art date
Application number
EC2001004068A
Other languages
English (en)
Inventor
Alya Zolotorev
Nathalie A Dubois-Stringfellow
Steve Roczniak
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of ECSP014068A publication Critical patent/ECSP014068A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se encontró que la proteína Ryk tenia una novedosa actividad en la regulación de la angiogenesis, se construyeron nuevas proteínas Ryk variantes que son ventajosas para modular la actividad formadora de capilares de las células endoteliales, las proteínas Ryk variantes pueden ser utilizadas como agentes terapéuticos en enfermedades tales como el cáncer, la cicratización de heridas, las retinopatías diabéticas, la degeneración macular y las enfermedades cardiovasculares, así como otras enfermedades o trastornos clínicos en la que la angiogenesis esta involucrada en la causa o el tratamiento de la enfermedad.
EC2001004068A 2000-05-10 2001-05-09 Procedimiento para regular la angiogenesis utilizando proteina ryk ECSP014068A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10

Publications (1)

Publication Number Publication Date
ECSP014068A true ECSP014068A (es) 2002-02-25

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2001004068A ECSP014068A (es) 2000-05-10 2001-05-09 Procedimiento para regular la angiogenesis utilizando proteina ryk

Country Status (13)

Country Link
EP (1) EP1287121A2 (es)
JP (1) JP2004527206A (es)
AR (1) AR028424A1 (es)
AU (1) AU2001261343A1 (es)
CA (1) CA2408349A1 (es)
CO (1) CO5300464A1 (es)
DO (1) DOP2001000164A (es)
EC (1) ECSP014068A (es)
GT (1) GT200100079A (es)
PE (1) PE20011218A1 (es)
SV (1) SV2002000442A (es)
UY (1) UY26696A1 (es)
WO (1) WO2001085789A2 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501523B2 (en) 2014-07-18 2019-12-10 Sanofi IL-8 level based method of predicting the outcome of colon cancer treatment
US11033606B2 (en) 2011-04-26 2021-06-15 Sanofi Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471934A2 (en) * 2002-02-06 2004-11-03 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Kinases involved in the regulation of energy homeostasis
TW202315894A (zh) * 2021-08-18 2023-04-16 美國加利福尼亞大學董事會 抗受體相關酪胺酸激酶（ｒｙｋ）抗體及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0646129A4 (en) * 1992-05-11 1995-07-19 Ludwig Inst Cancer Res MOLECULES, WHICH ARE SIMILAR TO THE TYROSIN KINASE OF THE RECEPTOR TYPE (01/13/94).
AU4606196A (en) * 1994-12-23 1996-07-19 Ludwig Institute For Cancer Research Assay, receptor proteins and ligands
WO1999064589A1 (en) * 1998-06-11 1999-12-16 Astrazeneca Ab Human receptor tyrosine kinase
WO2000024415A2 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033606B2 (en) 2011-04-26 2021-06-15 Sanofi Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI)
US10501523B2 (en) 2014-07-18 2019-12-10 Sanofi IL-8 level based method of predicting the outcome of colon cancer treatment
US11208461B2 (en) 2014-07-18 2021-12-28 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer

Also Published As

Publication number Publication date
WO2001085789A3 (en) 2002-05-16
WO2001085789A2 (en) 2001-11-15
GT200100079A (es) 2001-12-31
JP2004527206A (ja) 2004-09-09
AU2001261343A1 (en) 2001-11-20
EP1287121A2 (en) 2003-03-05
UY26696A1 (es) 2001-12-28
PE20011218A1 (es) 2002-02-01
DOP2001000164A (es) 2002-05-15
SV2002000442A (es) 2002-07-03
CO5300464A1 (es) 2003-07-31
CA2408349A1 (en) 2001-11-15
AR028424A1 (es) 2003-05-07

Similar Documents

Publication Publication Date Title
UY28396A1 (es) Trompas de vegf y usos terapéuticos de las mismas
ATE290401T1 (de) Topisch anwendbare mittel gegen nagelpilzerkrankungen
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
BR9714363A (pt) Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas
IL117645A (en) Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
ATE339187T1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
DE59811158D1 (de) Verwendung von erythropoietin und eisenpräparaten zur herstellung von pharmazeutischen kombinationspräparaten zur behandlung von rheumatischen erkrankungen
ES2180629T3 (es) Usos terapeuticos de productos dimeros de proteina bactericida/aumentadora de la permeabilidad.
MXPA04005204A (es) Derivados de hidrazonipirazol y su uso como terpapeuticos.
ATE340561T1 (de) Verwendung von antiseptika zur herstellung von arzneimitteln zur prophylaxe und behandlung von entzündungen im korperinneren des menschen
DK1343472T3 (da) Thixotropisk næsespray
ECSP014068A (es) Procedimiento para regular la angiogenesis utilizando proteina ryk
ITRM970238A0 (it) Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella terapia di patologie corneali e congiuntivali
MX9701996A (es) Utlizacion de 3-oxo de 2, 4-diamino-pirimidina o una de sus sales en el tratamiento de desordenes dela maduracion y de la estructuracion del colageno.
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
DE60107444D1 (de) Verwendung einer pollenextrakt-enthaltenden verbindung zur behandlung von ödemen
ES2134254T3 (es) Expresion del factor osteogenico op-1 de celulas de spodoptera frugiperda infectadas con baculovirus recombinante.
ATE373482T1 (de) Pharmazeutische zusammensetzung zur lokalen behandlung von hauterkrankungen und hautwunden
DOP2001000141A (es) Proteina actuando como un modulador angiogenico
DE60112750D1 (de) Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
SV2002000362A (es) Proteinas que tienen una actividad moduladora de angiogenesis ref.msb-7265-sv
DE60222633D1 (de) Verwendung von matrixprotein für gesteuerte geweberegenerationen
SE9904863D0 (sv) New use
AR011907A1 (es) UTILIZACIoN DEL ACIDO 4-(2,2-DIMETILPROPANOL)BUTANOICO (PIVAGABIN)PARA PREPARAR UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE FORMAS DE ANSIEDADDEPRESIVA.